Synapse

← EJC Skin Cancer

Papers in EJC Skin Cancer

Page 1 · newest first

  1. Modality-Specific Prognostic and Predictive Factors in Metastatic Uveal MelanomaEJC Skin Cancer · 2026
  2. Ten-year outcomes after initial response to immune checkpoint inhibitors in patients with advanced Merkel cell carcinomaEJC Skin Cancer · 2026
  3. Predictors of clinical and pathological response in patients with basal cell carcinoma treated with BO-112, a novel intralesional treatmentEJC Skin Cancer · 2026
  4. Non-treatment as a valuable treatment option in older adults with basal cell carcinoma?EJC Skin Cancer · 2026
  5. PI3K Inhibition and PD-1 Blockade in Advanced Anal Canal CarcinomaEJC Skin Cancer · 2026
  6. Clinical and Patient-Reported Outcomes in C-POST: Phase 3 Trial of Adjuvant Cemiplimab versus Placebo for High-Risk Cutaneous Squamous Cell CarcinomaEJC Skin Cancer · 2026
  7. Bone metastases in melanoma: a real-world clinical and radiological descriptive analysisEJC Skin Cancer · 2026
  8. Extraskeletal Ewing Sarcoma of the Nail Unit Mimicking Subungual Melanoma: A Rare Acral EntityEJC Skin Cancer · 2026
  9. Real-world outcomes of palliative anti–programmed cell death protein 1 monotherapy in patients aged ≥75 years with advanced melanomaEJC Skin Cancer · 2026
  10. Radiotherapy Outcomes in Distal Limb Skin Cancers Treated at a Large District General HospitalEJC Skin Cancer · 2026
  11. Sarcoid-like reaction associated with immune checkpoint inhibitor: To be, or not to be, that is the question.EJC Skin Cancer · 2026
  12. Proteomic profiling identifies response-associated pathways in immunotherapy-treated melanomaEJC Skin Cancer · 2026
  13. De-escalation of targeted therapy in melanoma: A literature reviewEJC Skin Cancer · 2026
  14. Duration of sonidegib treatment and its relationship with recurrence after complete response: a multicenter retrospective studyEJC Skin Cancer · 2026
  15. Episode-Based Melanoma Risk Stratification Using Artificial Intelligence:Development and Validation of Time-Updated Prognostic ModelsEJC Skin Cancer · 2026
  16. Landmark overall survival of 89% at one year among patients with anti-PD1 refractory metastatic melanoma treated with evalstotug, a conditionally binding anti-CTLA-4 antibodyEJC Skin Cancer · 2026
  17. Successful Cemiplimab Therapy in a Very Elderly Patient with Cutaneous Squamous Cell Carcinoma: A Case ReportEJC Skin Cancer · 2026
  18. Therapeutic challenges in oral mucosal melanoma: two clinical casesEJC Skin Cancer · 2026
  19. Mortality trends of melanoma in Germany from 2001 to 2020EJC Skin Cancer · 2026
  20. Efficacy and safety of RP1 plus nivolumab in patients with non-melanoma skin cancerEJC Skin Cancer · 2026
  21. Multimodal vascular imaging of cutaneous neoplasms using dermoscopy, dynamic optical coherence tomography and line-field confocal optical coherence tomographyEJC Skin Cancer · 2026
  22. Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic MelanomaEJC Skin Cancer · 2026
  23. A Phase II Single Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy with Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)EJC Skin Cancer · 2026
  24. Genetic alterations and prognosis in extramammary Paget disease: potential roles of somatic CDKN2A variants in poor outcomesEJC Skin Cancer · 2026
  25. Beyond Clinical Exams: when AI-assisted multimodal imaging detects featureless dermoscopic basal cell carcinomaEJC Skin Cancer · 2026
  26. Malignant variant of a well-known entityEJC Skin Cancer · 2026
  27. Results of the Euromelanoma 2025 campaign in Spain.EJC Skin Cancer · 2026
  28. Onset of Poliosis is linked to Durable Response to Immune-Checkpoint Blockade in Metastatic Melanoma Patients: A Multicenter Case SeriesEJC Skin Cancer · 2026
  29. Immune-related pneumonitis: A retrospective analysis of corticosteroid requirements and the role of hydroxychloroquine in melanoma patientsEJC Skin Cancer · 2026
  30. 10-years of first-line ipilimumab and nivolumab in the management of melanoma brain metastases: a single centre experienceEJC Skin Cancer · 2026
  31. Immune-related GFAP-Astrocytopathy under PD-1 Inhibition: A Case ReportEJC Skin Cancer · 2026
  32. PD-L1 Assessment in Merkel Cell Carcinoma: Predictive Implications for Anti-PD-1 and Anti-PD-L1 TherapyEJC Skin Cancer · 2026
  33. Rapid reduction of immune checkpoint inhibitor–associated pruritus with nemolizumabEJC Skin Cancer · 2026
  34. Validation of a Prognostic microRNA Signature in Early-Stage Melanoma Across NanoString and RNA-Sequencing PlatformsEJC Skin Cancer · 2026
  35. Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025EJC Skin Cancer · 2026
  36. Comparative analysis of progression free survival and treatment maintenance in patients with advanced melanoma responding to first-line treatmentEJC Skin Cancer · 2026
  37. Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatmentEJC Skin Cancer · 2026
  38. Living with advanced or metastatic melanoma: A patient-driven conceptual modelEJC Skin Cancer · 2026
  39. Complete response with combined sonidegib and pembrolizumab in synchronous advanced basal cell carcinoma and metastatic cutaneous squamous cell carcinoma: A case reportEJC Skin Cancer · 2026
  40. Rethinking locoregional therapy of Merkel cell carcinoma in the era of immune checkpoint inhibitionEJC Skin Cancer · 2026
  41. Cutaneous Adenocarcinomas: Patterns of Presentation, Management, and Prognosis in a Five-Year Single-Center ExperienceEJC Skin Cancer · 2026
  42. Dermatofibrosarcoma protuberans in South Africa: Outcomes of staged excision and peripheral and deep en face margin assessment (PDEMA) and recommendations for wide local excision marginsEJC Skin Cancer · 2026
  43. Registry-based survival analysis of high-risk melanoma patients in Serbia: the impact of adjuvant treatment for stage III diseaseEJC Skin Cancer · 2026
  44. The recurrence rate of malignant melanoma treated with staged micrographic excision in South Africa: A retrospective studyEJC Skin Cancer · 2026
  45. Long-term outcomes of cutaneous basal cell and squamous cell carcinomas with < 1 mm close primary surgical excision margins managed in a UK tertiary centre multidisciplinary teamEJC Skin Cancer · 2026
  46. Neutropenia induced by dabrafenib and trametinib combination therapy in patients with melanoma: Incidence, risk factors and clinical implicationsEJC Skin Cancer · 2026
  47. From immune activation to pathological response: neoadjuvant immunotherapy in cutaneous squamous cell carcinoma. A systematic review and meta-analysisEJC Skin Cancer · 2026
  48. Exceptional case of tumor lysis syndrome following Encorafénib-Binimétinib therapy for metastatic melanomaEJC Skin Cancer · 2026
  49. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced cutaneous squamous cell carcinomaEJC Skin Cancer · 2026
  50. BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter studyEJC Skin Cancer · 2026